Recursion Pharmaceuticals, Inc. (RXRX) stock
RXRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 8/302% below fair value
$2.90−0.28 (-8.79%)
Close on Nov 16, 2026Market cap $1.56BP/E –Yield –
Recursion Pharmaceuticals operating margin
Operating margin is operating income as a percentage of revenue.
Recursion Pharmaceuticals's operating margin for the twelve months ending Jun 30, 2026 was -991.7%. For fiscal 2025 it was -867.9%, against -814.1% the year before. The highest annual figure on record is -616.7% in fiscal 2022.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -867.9% | −53.8 |
| FY2024 | Dec 31, 2024 | -814.1% | −28.8 |
| FY2023 | Dec 31, 2023 | -785.3% | −168.6 |
| FY2022 | Dec 31, 2022 | -616.7% | +1179.0 |
| FY2021 | Dec 31, 2021 | -1795.8% | +339.9 |
| FY2020 | Dec 31, 2020 | -2135.7% | +556.9 |
| FY2019 | Dec 31, 2019 | -2692.6% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -1759.7% | −842.9 |
| Q1 FY2026 | Mar 31, 2026 | -1985.6% | −687.7 |
| Q4 FY2025 | Dec 31, 2025 | -304.8% | +3737.6 |
| Q3 FY2025 | Sep 30, 2025 | -3327.6% | −2950.5 |
| Q2 FY2025 | Jun 30, 2025 | -916.8% | −219.4 |
| Q1 FY2025 | Mar 31, 2025 | -1297.9% | −599.4 |
| Q4 FY2024 | Dec 31, 2024 | -4042.4% | −3134.0 |
| Q3 FY2024 | Sep 30, 2024 | -377.1% | +568.0 |
| Q2 FY2024 | Jun 30, 2024 | -697.4% | +44.3 |
| Q1 FY2024 | Mar 31, 2024 | -698.4% | −122.6 |
| Q4 FY2023 | Dec 31, 2023 | -908.4% | −462.5 |
| Q3 FY2023 | Sep 30, 2023 | -945.1% | −469.6 |
| Q2 FY2023 | Jun 30, 2023 | -741.7% | +120.8 |
| Q1 FY2023 | Mar 31, 2023 | -575.8% | +473.9 |
| Q4 FY2022 | Dec 31, 2022 | -445.9% | +2118.6 |
| Q3 FY2022 | Sep 30, 2022 | -475.5% | +1355.7 |
| Q2 FY2022 | Jun 30, 2022 | -862.5% | +743.2 |
| Q1 FY2022 | Mar 31, 2022 | -1049.7% | +140.1 |
| Q4 FY2021 | Dec 31, 2021 | -2564.5% | −1613.9 |
| Q3 FY2021 | Sep 30, 2021 | -1831.2% | +361.4 |
| Q2 FY2021 | Jun 30, 2021 | -1605.7% | +8188.4 |
| Q1 FY2021 | Mar 31, 2021 | -1189.9% | +29381.8 |
| Q4 FY2020 | Dec 31, 2020 | -950.6% | – |
| Q3 FY2020 | Sep 30, 2020 | -2192.6% | – |
| Q2 FY2020 | Jun 30, 2020 | -9794.1% | – |
| Q1 FY2020 | Mar 31, 2020 | -30571.7% | – |
See a number that looks wrong?